Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
about
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's diseaseAzathioprine or 6-mercaptopurine for induction of remission in Crohn's diseaseUtilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel diseaseModel-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.Teratogen update: azathioprine and 6-mercaptopurine.Novel approaches to inflammatory bowel disease.A Comparative Analysis of Drug-Induced Hepatotoxicity in Clinically Relevant Situations.Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature.Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel diseaseAzathioprine, Mercaptopurine, and 5-Aminosalicylic Acid Affect the Growth of IBD-Associated Campylobacter Species and Other Enteric MicrobesDrug choices in autoimmune hepatitis: part B--Nonsteroids.Genes and beans: pharmacogenomics of renal transplant.Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.Pharmacokinetic modeling of therapies for systemic lupus erythematosus.CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients.Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease.Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.Application of liposomes in treatment of rheumatoid arthritis: quo vadis
P2860
Q24197676-B133EB66-E241-491E-838A-E36C27C6D8FBQ24240676-5585F83B-F269-480C-8EE6-E70C1E9AB0D6Q28362619-EB6D701D-274F-4C13-BB33-6CC3FCAB5596Q30838395-FABAA60E-F72A-45C0-A553-AD09A97D9D98Q34124884-FA0A63C7-F7FE-4CBF-A503-D4994D7C6C68Q36181229-E3741925-E0D8-426F-A327-D91BFFE79ED7Q36267296-43671FB3-4F93-40DD-8E1F-B1FFAB11C28EQ36371451-FC0B4447-75ED-42CC-9CAA-F6DCB3F0317EQ36989959-956F2F1E-6D2D-4339-98A7-7F3DC2968E3CQ37729532-18C327A9-EA72-404E-B538-CDD577417903Q38051706-3A7ABE48-33F7-4CC9-A177-525471EE98C8Q38104742-1726A6E6-7CBA-4D18-BC5E-C98EC1EEEF8DQ38383015-E7FEFB6D-5857-46B1-89B3-ADC2675F4EA6Q38542910-EB3981D0-DE8A-478A-822A-526C9F6975E1Q39744964-D9C03C98-4342-4B61-A49F-2F0BB321FF7EQ42775209-4F903731-611B-43A4-85BD-945D89523CD1Q42788628-79F7D286-3A89-4F92-A3D9-D37B68D39125Q45151580-A91EB2B9-A17C-4B47-AC3B-6BF95DBDA08DQ59101195-6DE85C5C-C417-4D43-8B97-0F516215D413
P2860
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@ast
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@en
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@nl
type
label
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@ast
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@en
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@nl
prefLabel
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@ast
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@en
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@nl
P2093
P2860
P356
P1433
P1476
Azathioprine pharmacokinetics ...... nd rectal foam administration.
@en
P2093
A R Zinsmeister
D W Mahoney
E C Van Os
J J Lipsky
P2860
P356
10.1136/GUT.39.1.63
P407
P577
1996-07-01T00:00:00Z